GLMD (Galmed Pharmaceuticals) Total Equity: $15.78 Mil (As of Dec. 2025)


GLMD Galmed Pharmaceuticals Ltd GLMD
27 GF Score
Price $0.59
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals Total Equity?

Galmed Pharmaceuticals GLMD +2.71% 27 Total Equity is $15.78 Mil as of Dec. 2025. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

Galmed Pharmaceuticals's total equity for the quarter that ended in Dec. 2025 was $15.78 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Galmed Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals Total Equity Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.50 13.42 13.88 16.33 15.78

Galmed Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.33 16.88 20.52 19.11 15.78
GLMD
27GF Score
Galmed Pharmaceuticals Ltd GLMD
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Galmed Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=18.627-2.845
=15.78

Galmed Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=18.627-2.845
=15.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $15.78 Mil mean?
Galmed Pharmaceuticals (GLMD) has a Total Equity of $15.78 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Galmed Pharmaceuticals and its competitors.
Is Galmed Pharmaceuticals' Total Equity too high?
Galmed Pharmaceuticals' current Total Equity is $15.78 Mil. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' Total Equity compare to RNAZ and ARTL?
Galmed Pharmaceuticals' Total Equity of $15.78 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Galmed Pharmaceuticals and its competitors. Galmed Pharmaceuticals's current Total Equity is $15.78 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current Total Equity of $15.78 Mil. The current Total Equity is $15.78 Mil. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current Total Equity is $15.78 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score

Get the complete analysis for GLMD

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.59
Price